Curcumin attenuates the expression of IL-1β, IL-6, and TNF-α as well as cyclin E in TNF-α-treated HaCaT cells; NF-κB and MAPKs as potential upstream targets

International Journal of Molecular Medicine

Volumn 19, Issue 3, 2007, Pages 469-474

  Cho, Jae We ^a   Lee, Kyu Suk ^a   Kim, Chang Wook ^a  

^a Keimyung University   (South Korea)

Author keywords

Curcumin; Cyclin E; HaCaT cells; IL 1 ; IL 6; NF B; TNF

Indexed keywords

CURCUMIN; CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KERATINOCYTE; METABOLISM;

CURCUMIN; CYCLIN E; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; KERATINOCYTES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947532054     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.3.469     Document Type: Article

References (24)

1. Gaspari AA: Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 54 (3 Suppl 2): S67-S80, 2006.
2. Pierard-Franchimont C and Pierard GE: Etanercept (Enbrel) for the treatment of moderate to severe plaque type psoriasis. Rev Med Liege 61: 201-205, 2006.
3. Cassano N, Loconsole F, Coviello C and Vena GA: Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 19: 237-240, 2006.
4. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK and Looney RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol 25: 1544-1552, 1998.
5. Mascia F, Mariani V, Girolomoni G and Pastore S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163: 303-312, 2003.
6. Torii S, Yamamoto T, Tsuchiya Y and Nishida E: ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci 97: 697-702, 2006.
7. Santiskulvong C, Sinnett-Smith J and Rozengurt E: EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin. Am J Physiol Cell Physiol 281: C886-C898, 2001.
8. Wajant H, Pfizenmaier K and Scheurich P: Tumor necrosis factor signaling. Cell Death Differ 10: 45-65, 2003.
9. Islam Z, Gray JS and Pestka JJ: p38 Mitogen-activated protein kinase mediates IL-8 induction by the ribotoxin deoxynivalenol in human monocytes. Toxicol Appl Pharmacol 213: 235-244, 2006.
10. Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, Madsen M, Binderup L, Skak-Nielsen T, Fjording MS and Iversen L: Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 176: 1431-1438, 2006.
11. Oz-Arslan D, Ruscher W, Myrtek D, Ziemer M, Jin Y, Damaj BB, Sorichter S, Idzko M, Norgauer J and Maghazachi AA: IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids. J Leukoc Biol 80: 287-297, 2006.
12. Shishodia S, Sethi G and Aggarwal BB: Curcumin: getting back to the roots. Ann NY Acad Sci 1056: 206-217, 2005.
13. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223: 181-190, 2005.
14. Campbell FC and Collett GP: Chemopreventive properties of curcumin. Future Oncol 1: 405-414, 2005.
15. Kim JH, Xu C, Keum YS, Reddy B, Conney A and Kong AN: Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27: 475-482, 2006.
16. Grandjean-Laquerriere A, Gangloff SC, Le Naour R, Trentesaux C, Hornebeck W and Guenounou M: Relative contribution of NF-kappaB and AP-1 in the modulation by curcumin and pyrrolidine dithiocarbamate of the UVB-induced cytokine expression by keratinocytes. Cytokine 18: 168-177, 2002.
17. Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G and Ichikawa H: TNF blockade: an inflammatory issue. Ernst Schering Res Found Workshop 56: 161-186, 2006.
18. Rozieres A, Hennino A and Nicolas JF: TNF alpha in the physiopathology of psoriasis. Ann Dermatol Venereol 133: 174-180, 2006.
19. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W and Edwards CK III: Biology of tumor necrosis factor-alpha - implications for psoriasis. Exp Dermatol 13: 193-222, 2004.
20. Liu ZG: Molecular mechanism of TNF signaling and beyond. Cell Res 15: 24-27, 2005.
21. Han SS, Keum YS, Seo HJ and Surh YJ: Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol 35: 337-342, 2002.
22. Kang G, Kong PJ, Yuh YJ, Lim SY, Yim SV, Chun W and Kim SS: Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 94: 325-328, 2004.
23. Leclercq IA, Farrell GC, Sempoux C, dela Pena A and Horsmans Y: Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 41: 926-934, 2004.
24. Suh SJ, Jin UH, Kim SH, Chang HW, Son JK, Ho Lee S, Son KH and Kim CH: Ochnaflavone inhibits TNF-alpha-induced human VSMC proliferation via regulation of cell cycle, ERK1/2, and MMP-9. J Cell Biochem (In press).